Overview

A Study of CNSA-001 in Women With Diabetic Gastroparesis

Status:
Completed
Trial end date:
2019-10-08
Target enrollment:
Participant gender:
Summary
This study evaluates CNSA-001 in the treatment of women with moderate to severe diabetic gastroparesis. Half the patients will receive CNSA-001, while the other half will receive a placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Censa Pharmaceuticals, Inc.
PTC Therapeutics